PROCESS OF DELIVERING A POLYNUCLEOTIDE TO A CELL VIA THE VASCULAR SYSTEM

• US 20010009904A1
• Filed: 04/30/1998
• Published: 07/26/2001
• Est. Priority Date: 12/30/1997
• Status: Abandoned Application

• Current Assignee: Dr. Jon A. Wolff, Stuart J. Knechtle, Vladimir G. Budker
• Original Assignee: Dr. Jon A. Wolff, Stuart J. Knechtle, Vladimir G. Budker
• Inventors: WOLFF, JON A., BUDKER, VLADIMIR G., KNECHTLE, STUART J.
• Application Number:
  US09/070,303
• Publication Number:
  US 20010009904A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition

Abstract

A process for delivering a polynucleotide into a parenchymal cell in a mammal, comprising, transporting the polynucleotide into a blood vessel communicating with the parenchymal cell in tissue or organ of the mammal such that the polynucleotide is transfected into the parenchymal cell. More specifically, the parenchymal cell consists of a parenchymal cell and the polynucleotide consists of a viral vector.

Claims

1. A process for delivering a polynucleotide to a parenchymal cell, comprising:

inserting the polynucleotide into a vessel for delivery to the cell such that the polynucleotide is transfected into the cell.

2. The process of

claim 1

wherein the polynucleotide is selected from the group consisting of natural RNA, DNA and non-natural polynucleotides.

3. The process of

claim 2

wherein the polynucleotide is a viral vector.

4. The process of

claim 3

wherein the polynucleotide is a vector selected from the group consisting of adenoviral, adenoassociated viral and retroviral.

5. The process of

claim 1

wherein the vessel consists of a blood vessel having a permeable wall.

6. The process of

claim 5

wherein the blood vessel is selected from the group consisting of afferent and efferent vessels.

7. The process of

claim 7

wherein the permeability is increased by a method selected from the group consisting of increasing hydrostatic pressure on the blood vessel wall, increasing osmotic pressure on the blood vessel wall, and introducing a biologically-active molecule to the blood vessel wall.

8. The process of

claim 8

wherein the hydrostatic pressure is increased by obstructing outflow from the blood vessel.

9. A process for delivering a polynucleotide to a cell, comprising:

a) forming the polynucleotide for binding with a molecule selected from the group consisting of RNA, DNA, nucleic acid hybrids, derivatives of natural nucleotides and protein; and

,

b) inserting the polynucleotide into a vessel for delivery to the cell.

10. The process of

claim 9

wherein the polynucleotide comprises a natural or non-natural polynucleic acid for preventing expression.

11. The process of

claim 10

wherein the polynucleotide comprises anti-sense.

12. The process of

claim 11

wherein the vessel consists of a blood vessel having a permeable wall.

13. The process of

claim 12

wherein the blood vessel is selected from the group consisting of afferent and efferent vessels.

14. The process of

claim 13

wherein permeability is increased by a method selected from the group consisting of:

increasing hydrostatic pressure on the blood vessel wall, increasing osmotic pressure on the blood vessel wall, and introducing a biologically-active molecule to the blood vessel wall.

15. The process of

claim 14

wherein the hydrostatic pressure is increased by obstructing outflow from the blood vessel.

16. A process for delivering a polynucleotide to a cell, comprising:

a) forming the polynucleotide to recombine with a molecule selected from the group consisting of RNA and DNA, nucleic acid hybrids, and derivatives of natural nucleotides; and

,

b) inserting the polynucleotide into a vessei for delivery to the cell.